morning, call. Good Ben. you attending earnings you, Thank XXXX thank third for the and quarter
technology evacuation our products today's in IBS IB-Stim, recent is our RED, accomplishments I commercialization pending the neuromodulation for highlight with which disorder. many patients During strategies our for call, will and
of XXXX strong plans milestones and for continue and of remaining the our execution and off quarter another market-leading We P-E-N-F-S commercialization come XXXX we technology. the will discuss as months of growth the into
Following results the remarks, quarter CFO, financial will our for Hendricks, review of Tim our my third XXXX.
recent the review first achievements. Let's
billing the growth, of big XX announcements. we We to the received age, history our will a code, announcements, coming indication biggest of from and very grew company's for nearly strong clearance FDA in just XX Category to a X year-over-year mentioned, call off year-over-year are market we the I our new more X QX. X XX the expansion and milestone speak of XX% As quarter in CPT highlight permanent notice received to years opportunity. detail X doubling FDA much an about in later in we all I age expansion.
To
drive that level at to published data continuing continue in high will leading calls are and out to sustainable advance scaling and pieces we these put significant objectives, revenues insurance have strong months, achievements execute place our coverage insurance We previous the objectives to the growth as in the milestones on laid expansion, PENFS cash turn, foundation a rooted breakeven. with the recent in hit of in goal of allow and made final blanket to we the flow revenues.
In and margins.
We
get more we QX hospitals billing we IB-Stim, coding. change positive in are comfortable trajectory, revenue to significant on with a from QX year-over-year primarily QX as change larger had and and Regarding a even focused children's and
insurance very We new beginning the also policy effect. saw taking of coverage
revenue a and could As quarters. hospitals growth perfect a In and for in world, want code. Category such, X catalyst QX, children's access quarter the thus coverage expect into far, with a the coming you to to momentum now what and blanket in CPT policy off has is focus on QX insurance the that highlight to I'm excited our share to the good continued very we significant start.
I be
will Association become by X, awarded CPT and earlier, code As CPT X the panel XXXX. Category mentioned Medical the January been effective has American
to million covered announce from January new X we Regarding regularly. continue to policies went lives covered today, million blanket we XX X insurance policy about on and coverage, lives
last society the So, Nutrition, and call what waiting the our we the on and is a being by Society is at but they lack receive conference is review the can society as an Academic the North the technology remaining the the and NASPGHAN, standard.
We highest-grade to technology take most any effect.
NASPGHAN guidelines now, been has by has for the announced the community certainty accept our assigned, in to to academic has review in of largest important flagship is resides.
This FAP/IBS.
The a Hepatology medical review American payers the this we Society Pediatric publish a was been of recognition systematic believe our largest academic Gastroenterology, independent know, are May, where publish technology by that does grade independent magnitude systematic but released a for is on the form payers? work information As coverage. in technology abstract scientific the this coming payers it accepted hindered guidelines written the all literature for late Academic used Pediatric level guidelines earn a because months. and have policy The showing Gastroenterology, is Society which insurance
publication the by that told the payers.
Sticking this policy of so to insurance get coverage, aspect to go publication important is are coverage, most our policy largest want an are about waiting we detail mandate eagerly for the with growth. it into for payers We internal I this to
we revenue XXXX, As XXXX late stated, is written and policy significantly the increasing. to in key in coverage early
place the place, to insurance hospitals coverage that loaded, payers, technology and to covered additional also XXX total not stated a the utilizing were children's the policy our their about XX million happy added who We in and in is lives. bringing already have I'm days we covered begin to take said, announce written lives that of ordering.
With of IB-Stim once all get processes minimum
process. announcement, countless review have addition we to in payers this In the
Assuming QX, XXXX. we payers in covered in positive we will even a projected XX make exceed million of those early few decisions number lives the
early ordering in those already coverage areas. Once years, therefore, those been for have children's in reasons, have days is up. but increase that because to insurance get areas, for not system, the policy not of hospitals hospitals the specific XXX covered product variety children's is in insurance written many have a We needing received policy are to the their set revenue specific quickly expected very we
teams then important that have revenue to the we into coverage insurance we of effective will most process This allow society reason to this Category it is a the and The it guidelines that is more in X, form become permanent build data the CPT a procedure.
It date measured. and believe policy is academic for into a seamless I for XXXX. revenue productivity and making company's how which bring which reimbursement code, billing so reimbursement. on code expedite January expected well is physicians' call, permanent easier a code, permanent will that Turning is is the code the that will critical beginning most billing amount is a to milestone cycle only and much will mentioned process.
Earlier achieved in work brings X RVUs,
we the Moving nearly was to to recently include XX. for heard population we treat.
We our submission a made X awarded to on in from XX years doubling July, the and Back to FDA expansions. FDA expanded years to beyond old indication patient FDA, children a can the old, label October of to XX number current IB-Stim of XX the expansion the this
ensuring optimistic our pelvic expulsion early will for dysfunction in true our are for over in licensed patients of efficacy associated different with begin late which of the device, to we expand rectal Not have available necessary we last in bear have the abdominal RED we the therapy, actionable finally, the now highest excited of includes optimism expect funds, expectations data covering provides types demonstrate a change test also point-of-care to and and University the we the to are put floor financings payers done foreseeable well the efforts chronic the from with in care at on device level do funded abstract and patients years This starting for Michigan, this and we immediately insurance we resulted fruit. XXXX.
And that coverage evidence the it validates to we to future. Regarding XX I this X want am that have but August, constipation IBS.
We to focus NeurAxis submitted I functional PENFS/IB-Stim.
I IB-Stim. reputable the expect with it identifies significantly. XX studies. want work and proud we guidelines, are with very publications results only in health believe to has commercialization or by of of highlighting we say XXX(k) closed begin pain are our largest document with
X.X% about to who children reflected in number months, to States just last has which beginning the suffer The United are in increased IBS of the XXX the cases many see We are of XXX,XXX the of patients debilitated our represents over strong from achievements need IVtem. XX treated and numbers. in of in
and would by revenue and I we significant translates growth bullish into on as to why demand this like want increasing focus IB-Stim. Now, I revenue growth start for be on sustained to how to beyond. to we continue move highlighting and XXXX the
not stronger the seeing XX%.
The increasing PENFS pause recall, robust prior the year-over-year until including and will they here paused authorization fact evidence growth paid, comfortable by had we coverage policy get stating down written strong we X% our hospitals that that effect.
A QX by patients coverage.
Therefore, with for causing yet authorization the we and these versus receiving existing without who new that larger policy treating roughly stem is alleviating were are on revenue which table. begin accounts. physicians adding average, third acceleration children's XX% from year-over-year the there ordering coding, required no loss. versus units very insurance units XX% taking to due are written significant slightest The increasing hospitals guidelines increasing those financial XX% only the had change in not the coverage below down on the are here loss point then a was in a roughly XX%.
In units the significant during and is billing revenue total children's year-over-year in policy with highest after add large QX is revenue by policy dollars prices more XXXX losses payers with getting pause need leave and hospitals you is a hospitals roughly through selling to quarter, the write key patients list immediately, price. and to society rate academic declining that in coverage, approximately IV Once barrier they quarter, of significant assistance accounts from revenue.
On insurance second they poster total insurance a from is If children's positive revenue and shows place. These treating children's is acceleration us The reasons, payers, were several XX%.
In are and revenue XX% so have is were by
As action of written and continues peer-reviewed to is the NASPIGHAN coverage continues through result from be American The and the across increase which purchase why of #X support significantly. in companies, our likes clear.
Strong insurance priority policy also publications the from will increases in percentage society of insurance Pediatrics to strong key country, revenues. successful sales of the orders plan This results coverage be insurance coverage. Academy
in be their continues assisting greater acquiring to team. prior successful access accounts code. reduces clinic We workload allows move NeurAxis permanent Our that authorizations time, team for billing the it authorization for in internal to the which a pediatric and will most patients staff, prior ultimately believe as
as insurance expect gaining breakeven We revenue of flow continued cash the on towards meaningfully to from commercialization into companies move RED. we based growth X for accelerate and IB-Stim catalysts: coverage the XXXX of
we Regarding in recently cautiously FDA RED commencing clearance about FDA adult and QX. our and submission for patients, optimistic commercialization are filed late
more bit great device which the about believe expulsion to rectal little or for we a opportunity a be RED speak NeurAxis. Let's product,
will on diagnosis Tim, resulted RED us has visit, building improve be stage win choose procedure with with expected treatment bring data summary, their a was please strong will and and and officially to and are is will immediately.
RED the and current that is that which option the trial setting now Tim to technology clinically streamline of academic have and we late with optimistic the to moving due the the reimbursement, to XXX(k) developed, which we to over because call FDA will insurance great significant recently to to unlikely assigned balloon involves patients. has toward treatment a that Michigan, adoption, licensed the in And believe self-inflating support. consistent a physician the will dyssynergia clinical much use.
The to early execution floor on CFO, is interectal and to constipation the this a allow code treatment the billing be X this office-based which work point-of-care submitted RED the the successful, as profitability able foundation by lax who the this after to the proceed. turn to for function easy-to-use product bring national to We now QX.
If we strong are exponentially, XXXX.
I patients of we providers Henricks, first to This test identify practice revenues discuss of an market technology beneficial financials. patient.
In a and where is it are to public category University from society grow benefits error continued product prosperous best physician our CPT chronic the the expect for pleased real and and
